Glow Peptides · Research Journal
CJC-1295 and Ipamorelin COA: Verifying a Two-Part Lot
Glow Peptides Research Team · 2026-09-18
For research use only. Not for human or veterinary use, diagnostic use, or in any therapeutic application.
CJC-1295 and Ipamorelin are sold together as one vial, and that single fact changes what a certificate of analysis has to do. Two named components mean two separate analytical questions, and a document answering only one of them — or answering both at once with a single number — has not described the material. This guide sets out what a two-component certificate must show, how to tell an attributed result from an aggregate one, and what it looks like when the same product has more than one published record. Both lots cited below open in the COA directory without an account.
If you have not read a certificate before, the field-by-field walk through the document layout is in the shorter guide on how to read a peptide certificate of analysis, and the longer account of the same ground is in certificates of analysis explained. This page assumes that groundwork and goes after the harder case: a document that has to carry two results and stay readable.
Why two named components change the document
A certificate for a single-component material has a straightforward job: one compound, one identity result, one purity result, one lot. Put two named compounds in the same vial and the structure has to change with it. There is no such thing as the purity of a two-component mixture, because purity is a statement about one substance relative to everything else detected alongside it. Ask for the purity of a vial containing two intended compounds and the question has no answer: each of them is, from the other's point of view, the something else. The only version of the question that means anything is asked twice. How pure is the CJC-1295 component. How pure is the Ipamorelin component.
That is why a two-component material is the clearest case in the catalog for a point that applies everywhere: a purity number is only evidence when you know what it is a number about. On a single-component vial the answer is obvious enough that nobody asks. On a two-component vial the answer has to be printed, and when it is not printed the number has quietly stopped being evidence while keeping the appearance of it.
So the test for a certificate on this pairing is not whether it contains a high figure. It is whether every result on the page is attributable — whether you can point at a line and say which of the two compounds it describes.
Attributed results and aggregate figures
An attributed result names its component. An aggregate figure describes the vial as a whole and leaves the reader to assume it applies to both. They can look almost identical on the page, and they carry completely different amounts of information.
What attribution looks like
On a well-formed two-component certificate, the results section is a small grid rather than a list. Each named component has its own row. Each row carries its own identity confirmation and its own purity figure, with the method stated. The specification of ≥99.2% appears as a floor against each component, not once at the bottom of the page. Nothing in that layout is difficult; it just requires the laboratory to have run and reported the analysis per component rather than per container.
The practical reading test takes a few seconds. Cover the top of the document with your hand so the product name is hidden, then look at each result line in isolation. If you can still tell which compound it belongs to, the result is attributed. If the line only makes sense because you remember what the product is called, it is an aggregate figure wearing an attributed layout.
What an aggregate figure hides
One unattributed percentage on a two-component document is consistent with several quite different underlying realities, and it cannot distinguish between them.
| What the document shows | What may be true underneath | Why the reader cannot tell |
|---|---|---|
| One purity figure, no component named | Both components individually clear the specification | This is the case the reader assumes, and it is the only one the figure is normally taken to mean |
| One purity figure, no component named | One component clears the specification comfortably; the other does not | A combined figure is weighted by how much of each component the detector saw, so a shortfall in the smaller contributor barely moves it |
| One purity figure, no component named | The two components were not separated and were integrated as a single peak | Nothing on the page distinguishes one merged peak from one genuine peak |
| One identity confirmation, one mass reported | Only one of the two named compounds was actually confirmed | A single mass is a statement about a single molecule; the second component is simply unaddressed |
| Identical figures printed for both components | One number was entered twice rather than measured twice | Two independent chromatographic integrations landing on the same value is unusual enough to be worth a question |
The second row is the one worth sitting with, because it is the failure an aggregate figure is structurally good at hiding. Where two components are not present in equal proportion — and there is no reason to assume they are — a combined number is dominated by whichever contributed more detected signal. The minor contributor can carry a materially worse impurity profile without the combined figure moving much at all. An aggregate figure is therefore not merely less informative than two attributed ones. It is biased in a specific direction: towards concealing problems in the smaller component.
What resolved means on a chromatogram
Attribution is not a formatting preference; it depends on something physical happening in the column. Reverse-phase HPLC separates by hydrophobicity. The stationary phase is non-polar, the mobile phase starts polar and becomes progressively less so across the gradient, and each component partitions between the two according to its own chemistry. More hydrophobic material holds onto the stationary phase longer and leaves the column later. Chain length and side-chain composition both feed into that behaviour, which is why two peptides of different length and different sequence rarely move through the column in step.
Two components are resolved when the detector signal drops back towards baseline between them. That gap is what makes the arithmetic possible: with a return to baseline, the area under each peak can be integrated on its own, and neither borrows area from its neighbour. The area belonging to each component is then a quantity you can attribute, which is the whole basis of a per-component purity statement.
When two components co-elute, the opposite happens. The peaks overlap, the signal never returns to baseline between them, and the instrument sees one hump where there are two substances. Any integration across that hump is a single number describing a mixture. It is not wrong as a measurement; it is simply not attributable, and no amount of care in reading the document can recover the attribution afterwards.
This is the mechanism behind a specific and under-discussed failure: a method developed for a single-component material, applied unchanged to a two-component one. The gradient was never designed to separate these two substances, so it may not, and what comes back is one peak and one number. The method line on the certificate is the only place a reader can look for evidence that the separation was developed for the material in front of them. The instruments themselves, and what each one can and cannot establish, are covered in the guide on HPLC and mass spectrometry.
Identity has to be found twice
Purity attribution gets most of the attention here, but identity is where a two-component document fails more quietly.
Mass spectrometry confirms identity by comparing an observed mass-to-charge value against the mass computed from a sequence. That is a statement about one molecule. Two named components have two different molecular masses, because they are two different molecules of different length and composition. A document reporting one observed mass has confirmed one component. The other has not been addressed at all, and there is nothing in the phrase "identity confirmed" to tell you which of the two was tested.
So the identity section of a two-component certificate should name both compounds and report a finding against each. This is a lower bar than it sounds. The measurement is routine; the reporting is where it is dropped.
The product name does not pin down the molecule
There is a real naming subtlety in this family, and it matters exactly here. The same short name is used across the industry for materials that differ by a modification — a difference in the molecule itself, not in how the name is typeset. Two vials can carry the same product name and not contain the same substance.
We have covered that distinction in full elsewhere, in the article on CJC-1295 with and without DAC, and this page will not repeat it or assert which variant any particular lot contains. The point worth carrying across is narrower and is about the paperwork. Because the variants differ as molecules, they differ in computed mass. Which means the identity result on a lot's own certificate is the field that settles which one is in the vial. The product name is not that field, a marketing page is not that field, and an industry convention is not that field.
Two published lots of the same pairing
The arguments above are easier to check against something real. Two lots of this material are released and published, and they came from different production sites, which makes them a usable illustration of what batch-to-batch comparison actually involves.
| Element | First lot | Second lot | What the difference tells you |
|---|---|---|---|
| Lot number | 260202QLCP10 | 260410HPCP10 | Two distinct batches, two distinct records |
| Date element | 260202 | 260410 | A six-digit YYMMDD date attached to the run; the two runs are months apart |
| Site token | QL | HP | Different production sites. QL, HP, ZJ and SXH appear across the catalog; what they stand for is not published, so read them as opaque tokens |
| Catalog code | CP10 | CP10 | Identical, and that is the point: the code identifies the material and its vial content independently of when or where the batch was made |
| Material | CJC-1295 and Ipamorelin, 10 mg total peptide content | CJC-1295 and Ipamorelin, 10 mg total peptide content | The same product page, correctly, for both |
| Record | View certificate | View certificate | Two documents. A single document offered for both would be describing a product rather than a batch |
What the two strings do and do not establish
The two lot numbers differ in their date and site segments and agree on the catalog code. That is precisely what the catalog code is for. It is a short compound abbreviation followed by the total peptide content in milligrams, so CP10 is this pairing at 10 mg, and it stays constant while the surrounding elements move with the run. A -C suffix on a catalog code marks the capsule form of the same material rather than a vial. The full grammar of both kinds of string is laid out in the guide to peptide lot codes and catalog codes.
Two cautions about reading the strings. Punctuation varies between batches across this catalog, so copy the string from the label rather than reconstructing it from memory, and do not read an unhyphenated string and a hyphenated one as evidence of anything. And learn the grammar only so that you can tell a lot number from a catalog code and notice when you have been handed the latter. The structure is not a verification method. Anyone can print a string that follows a convention.
What comparing two records can show
What the comparison establishes is that the documentation is per batch. Two lots, two lot numbers, two records, each reachable on its own. It also lets you check that the structure is stable: the same named laboratory, the same stated methods, the same specification floor, and — the check this article exists for — both named components carrying their own results in both documents. A supplier whose second document is thinner than its first has told you something about how the first came to exist.
What the comparison does not establish is a trend. Two points are not a series, and neither document says anything about a third batch. Each lot's impurity profile belongs to its own run, because synthesis, cleavage and purification are repeated every time. The constant across lots is the specification, not the measured values: ≥99.2% is a floor every released lot has to clear, per component, rather than a number any particular lot is claimed to sit at. You will not find a purity figure for either of these two lots in this article, and that is deliberate. Read each lot's own record.
The milligram figure on a two-component vial
This is the most common misreading of a multi-component certificate, and it goes in the reader's favour by a factor of two. The 10 mg in CP10 is the total peptide content of the vial. It is the combined content across both components as analysed, not the content of either one individually. A reader who assumes the headline figure applies separately to each named compound has doubled the material in their head before reading a single result.
The figure is also not a quantity of anything to be used, and it does not correspond to any period of time. It appears on the certificate for the same reason a lot number does: so that the document can be tied to one specific sealed physical object and checked against it. Read it as an identifier of the container's contents, which is what it is.
One component, two, and more: the same logic scaled
The attribution rule does not have a special case for two. It scales with the number of named components, and seeing it on a larger blend makes the structure obvious.
| Named components | Example lot | Total peptide content per vial | What the results section has to carry | Record |
|---|---|---|---|---|
| One | 260312HPTB10, code TB10, TB-500 | 10 mg | One identity result and one purity result. Attribution is unambiguous because there is only one candidate | View certificate |
| Two | 260410HPCP10, code CP10, CJC-1295 and Ipamorelin | 10 mg total | Two identity results and two purity results, each naming its component. The floor of ≥99.2% applies per component | View certificate |
| Several | 260320HPKL80, code KL80, KLOW | 80 mg total | A result per named component, identity and purity both. One figure for the vial would aggregate every component into a single line | View certificate |
Two things about the KLOW row are worth stating plainly, because both are misread often. The 80 mg is the total across the vial — never the amount of any single component, and never a quantity of anything to be used. And the separation problem gets harder rather than easier as components are added: every substance has to be resolved from all the others as well as from its own impurities, and the chance that two of them sit close together on the gradient rises with each one added. A certificate on a larger blend that reports one number has aggregated several analytical questions into a line with no addressee.
The single-component row is the useful control. On the TB-500 record there is nothing to attribute, which is why a purity figure on a single-component certificate feels self-evident and why the habit of not asking what a number is about survives long enough to cause trouble on a blend.
Red flags on a two-component certificate
These are the patterns worth refusing on a multi-component document, in rough order of seriousness. The generic certificate failures — no lot number, a laboratory described rather than named, documentation only on request — apply here too and are covered in the general guide. The list below is specific to materials with more than one named component.
- One purity figure for two named components. The central failure. The number may be real and may even be good, and it is still not attributable to either compound. Nothing you can read on the page recovers the attribution.
- A result attributed to the blend rather than to a component. "Purity of blend" and similar phrasings are aggregate figures with a label that sounds specific. A mixture does not have a purity.
- One observed mass on a two-component document. One mass confirms one molecule. The second component has not been tested, and the document does not say which one was.
- Identical purity figures for every component. Two or more independent integrations rarely land on the same value. Repeated figures suggest a number entered once and copied down the column.
- A method that was clearly developed for a single compound. If the method line gives no indication that the separation was developed for this material, there is no evidence the components were resolved, and unresolved components cannot be reported separately.
- Component proportions presented as purity. How much of each component the vial contains and how pure each component is are two different quantities. A document giving the first and heading it as the second has answered a question nobody asked.
- A specification quoted once at the foot of the page. A floor that applies per component belongs against each component. Quoted once, it reads as a claim about the mixture, which is not a claim that can be true.
- An identity section that names the product instead of the compounds. The product name is the thing under test, not the finding. On this family in particular, only a mass result distinguishes the variants, so a name in the identity field is circular.
How this works here
Every released lot is analysed by an independent laboratory — Freedom Diagnostics, named on the certificates themselves — using reverse-phase HPLC for purity and mass spectrometry for identity. The published specification is a floor of ≥99.2%, and on multi-component material it applies per component rather than to the vial.
The records are published per lot rather than per product. The COA directory lists them, the QR code on a vial opens the record for that vial's own lot, and the material page links the lots published for this pairing. There is no account, no email address and no request in any of those routes. The per-compound index of published lot records does the same job for the rest of the catalog.
Two limits belong in the same paragraph as those statements. Analytical results are specific to the lot and to the method that produced them, so a figure from one record does not transfer to another lot. And a certificate describes material as analysed on a date, not afterwards. Both are properties of the document rather than complaints about it.
Frequently asked questions
What should a CJC 1295 and Ipamorelin certificate show?
Two of everything. Each named component needs its own identity confirmation by mass spectrometry and its own purity result by reverse-phase HPLC, with the method stated, and the ≥99.2% specification applies as a floor against each component rather than to the vial. Alongside that, the fields any certificate needs: the lot number printed on your vial, the laboratory named rather than described, and a report date belonging to the batch. A result you cannot attribute to one of the two compounds has not told you what you need.
Why is a single purity number not enough on a blend?
Because purity is a statement about one substance relative to everything detected alongside it, and a vial with two intended compounds has two of those statements to make. One unattributed figure is consistent with both components clearing the specification, with one clearing it while the other falls short, and with the two never having been separated at all. It cannot distinguish them. Worse, a combined figure is weighted by how much signal each component produced, so a shortfall in the smaller contributor barely moves it.
What does CP10 mean on the label?
It is the catalog code: a short compound abbreviation followed by the total peptide content of the vial in milligrams. CP10 is this two-component pairing at 10 mg total. The same code appears inside the lot number, which gives you a second check against the label. A -C suffix marks the capsule form of a material rather than a vial. The code stays constant across batches while the date and site elements around it change, which is exactly what makes it useful for matching a vial to a product record.
What does 10 mg mean on a two component vial?
It is the total peptide content across the whole vial, as analysed, not the amount of either component individually. Reading it as a per-component figure doubles the material in your head. It is also not a quantity of anything to be used and it does not correspond to any period of time. The figure exists on the certificate for the same reason the lot number does: so the document can be tied to one specific sealed container and checked against it field by field.
How do I compare two lots of the same blend?
Compare structure, not figures. Two released lots of this material are published, 260202QLCP10 and 260410HPCP10, and they differ in their date and site elements while sharing the catalog code CP10. Open both and check that each names the same laboratory, states the same methods, applies the specification per component, and reports identity and purity against both named compounds. What the comparison establishes is that documentation is per batch. What it cannot establish is a trend; two records say nothing about a third lot.